The Research Desk
A Phase 2 trial reported retatrutide outperforming earlier GLP-1 therapies on weight-loss endpoints, though cross-trial comparisons carry limits. A related liver-fat finding has since redirected part of its Phase 3 program toward metabolic liver disease. What these results mean outside a controlled trial is a separate question, one the published evidence can only partly answer.
In a 2023 Phase 2 trial, the highest dose of a single investigational compound produced a mean weight reduction of 24.2 percent at 48 weeks, more than double what earlier GLP-1 therapies had shown in comparable trials. That compound is retatrutide, and the number is real, published, and peer reviewed. What it means for anyone outside a clinical trial is a separate question, and one the data can only partly answer.
What retatrutide is
Retatrutide (also known by its development code LY3437943) is a synthetic peptide developed by Eli Lilly that acts on three hormone receptors at once: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. Its discovery and preclinical characterization were first published by Coskun and colleagues in 2022, describing a single-molecule agonist engineered to activate all three receptors with balanced potency, a departure from earlier single- or dual-agonist incretin therapies (Coskun et al., 2022).
The Retatrutide research compounds in Helix's catalog are supplied to that same synthetic sequence, manufactured to research-grade specifications for laboratory use.
The mechanistic picture
Retatrutide is studied for its potential role in combining three distinct signaling pathways in a single molecule. GLP-1 receptor activation is associated with reduced appetite and slowed gastric emptying. GIP receptor activation is thought to contribute to insulin sensitivity and may offset some GLP-1-related nausea. Glucagon receptor activation is unusual among incretin therapies, it increases energy expenditure but also raises blood glucose on its own, which is why balancing it against GLP-1's glucose-lowering effect is central to the drug's design.
In preclinical rodent models, the glucagon component was linked to substantial reductions in liver fat content, a signal that later shaped the compound's clinical development toward metabolic liver disease specifically (Coskun et al., 2022).
Where the human evidence stands
Human data on retatrutide is still limited to Phase 2 and Phase 3 trials, it has not completed the regulatory review required for approval in any market.
The first major human trial, a randomized, double-blind Phase 2 study in 338 adults with obesity, reported a mean weight reduction of 24.2 percent at the 12 mg dose after 48 weeks, compared with 2.1 percent for placebo. Gastrointestinal side effects were the most commonly reported adverse events and were dose-dependent (Jastreboff et al., 2023).
A dedicated Phase 2a sub-study focused on participants with elevated liver fat reported reductions in liver fat content of up to 86 percent at 48 weeks in the 12 mg group, versus a 4.6 percent increase in the placebo group. Among participants on the highest dose, 86 percent reached normal liver fat levels (under 5 percent), compared with none in the placebo group (Sanyal et al., 2024). This finding has since directed part of the compound's Phase 3 program toward metabolic dysfunction-associated steatotic liver disease specifically.
A 2025 systematic review and meta-analysis pooling the available randomized controlled trial data confirmed consistent, dose-dependent reductions in body weight, waist circumference, and fasting glucose across studies, while noting that gastrointestinal tolerability remained the main limiting factor at higher doses (Abouelmagd et al., 2025).
Phase 3 trials are ongoing as of 2026, including a dedicated diabetes trial (TRANSCEND-T2D-1) and a trial in obesity-related knee osteoarthritis, which reported positive topline results in December 2025. Full peer-reviewed data from these later-stage trials had not yet been published at the time of writing.
Regulatory status
Retatrutide has not received approval from the FDA, EMA, or any other regulatory body as of this writing. It remains an investigational compound studied under clinical trial protocols. This distinguishes it from already-approved incretin therapies such as semaglutide and tirzepatide, which retatrutide is frequently compared against in the research literature for its broader three-receptor mechanism.
Bottom line
The published evidence on retatrutide is genuinely substantial for an investigational compound at this stage: a completed Phase 2 trial, a dedicated liver fat sub-study, and a systematic review synthesizing the available randomized data, all in peer-reviewed journals. What is established is the compound's effect within controlled trial conditions, tracked by qualified investigators, on defined populations. What remains open is everything Phase 3 trials exist to answer: long-term safety, effect durability, and performance across broader populations. Helix supplies Retatrutide as a research compound for laboratory use, not for human or veterinary administration.
Frequently asked questions
What is retatrutide?
Retatrutide is a synthetic peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It was developed by Eli Lilly and is studied in clinical trials for obesity, type 2 diabetes, and metabolic liver disease.
Is retatrutide FDA approved?
No. As of this writing, retatrutide remains an investigational compound in Phase 3 clinical trials. It has not been approved by the FDA or any other regulatory agency.
How does retatrutide differ from semaglutide and tirzepatide?
Semaglutide activates the GLP-1 receptor alone. Tirzepatide activates GLP-1 and GIP receptors. Retatrutide adds a third target, the glucagon receptor, which researchers have studied for its potential role in energy expenditure and liver fat reduction, alongside the appetite and glucose effects shared with the other two.
What does the liver fat data show?
A Phase 2a sub-study reported liver fat reductions of up to 86 percent at 48 weeks in participants on the highest studied dose, the largest liver fat reduction reported for any drug in clinical development at the time of publication (Sanyal et al., 2024).
Is retatrutide studied for osteoarthritis?
Yes. A Phase 3 trial in adults with obesity-related knee osteoarthritis reported positive topline results in December 2025. Full peer-reviewed data was not yet published at the time of writing.
For research use only. Not for human or veterinary use. This article discusses published clinical research; it does not describe or endorse any use of Helix's research compounds outside of qualified laboratory research settings. For more on how Helix documents and sources its compounds, see our Science page.
Sources
- Coskun T, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." Cell Metabolism, 2022. PubMed PMID 35985340
- Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial." New England Journal of Medicine, 2023;389(6):514-526. PubMed PMID 37366315
- Sanyal AJ, et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial." Nature Medicine, 2024;30:2037-2048. PMC11271400
- Abouelmagd A, et al. "Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials." Baylor University Medical Center Proceedings, 2025. PMC12026077